Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 4/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6935760 | 0.80 | ADORA2A (0.33) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL23735330 | 0.79 | PRMT5 (0.32) | PRMT5WDR77 | |
| SCHEMBL20778077 | 0.78 | ADORA2A (0.40) | PRMT5WDR77ADORA2AADORA1 | |
| SCHEMBL24393322 | 0.77 | ADORA2A (0.32) | EIF2AK3ADORA2AADORA1YTHDC1 | |
| SCHEMBL19684532 | 0.77 | SRC (0.44) | — | |
| SCHEMBL19711584 | 0.77 | ADORA2A (0.37) | EIF2AK3PRMT5WDR77ADORA2AADORA1 | |
| SCHEMBL26357318 | 0.77 | PIK3CD (0.37) | ADORA2AADORA1 | |
| SCHEMBL26084925 | 0.75 | PRMT5 (0.30) | PRMT5WDR77 | |
| SCHEMBL22432845 | 0.74 | ADORA2A (0.30) | ADORA2AADORA1 | |
| SCHEMBL11922111 | 0.74 | SRC (0.31) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017213825-A1 | TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS | TABULA RASA HEALTHCARE, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | EIF2AK3 1299/4885PRMT5 1945/4885WDR77 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.